203 related articles for article (PubMed ID: 9928552)
21. Classification of ductal carcinoma in situ by gene expression profiling.
Hannemann J; Velds A; Halfwerk JB; Kreike B; Peterse JL; van de Vijver MJ
Breast Cancer Res; 2006; 8(5):R61. PubMed ID: 17069663
[TBL] [Abstract][Full Text] [Related]
22. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
[TBL] [Abstract][Full Text] [Related]
23. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
24. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
[TBL] [Abstract][Full Text] [Related]
25. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast.
Rudnicka L; Stachura J
Pol J Pathol; 2000; 51(3):137-43. PubMed ID: 11247396
[TBL] [Abstract][Full Text] [Related]
26. Predictors of disease progression in ductal carcinoma in situ of the breast and vascular patterns.
Adler EH; Sunkara JL; Patchefsky AS; Koss LG; Oktay MH
Hum Pathol; 2012 Apr; 43(4):550-6. PubMed ID: 21925705
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
Seth A; Kitching R; Landberg G; Xu J; Zubovits J; Burger AM
Anticancer Res; 2003; 23(3A):2043-51. PubMed ID: 12894577
[TBL] [Abstract][Full Text] [Related]
28. Minimal breast cancer: evaluation of histology and biological marker expression.
Dublin EA; Millis RR; Smith P; Bobrow LG
Br J Cancer; 1999 Jul; 80(10):1608-16. PubMed ID: 10408407
[TBL] [Abstract][Full Text] [Related]
29. Are epithelial cells in fat or connective tissue a reliable indicator of tumor invasion in fine-needle aspiration of the breast?
Maygarden SJ; Brock MS; Novotny DB
Diagn Cytopathol; 1997 Feb; 16(2):137-42. PubMed ID: 9067105
[TBL] [Abstract][Full Text] [Related]
30. Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review.
van Deurzen CH; Hobbelink MG; van Hillegersberg R; van Diest PJ
Eur J Cancer; 2007 Apr; 43(6):993-1001. PubMed ID: 17300928
[TBL] [Abstract][Full Text] [Related]
31. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma.
Douglas-Jones AG; Gupta SK; Attanoos RL; Morgan JM; Mansel RE
Histopathology; 1996 Nov; 29(5):397-409. PubMed ID: 8951484
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of ductal carcinoma in situ of the breast.
Lagios MD
J Cell Biochem Suppl; 1993; 17G():49-52. PubMed ID: 8007709
[TBL] [Abstract][Full Text] [Related]
33. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast.
Simpson JF; Quan DE; O'Malley F; Odom-Maryon T; Clarke PE
Am J Pathol; 1997 Jul; 151(1):161-8. PubMed ID: 9212742
[TBL] [Abstract][Full Text] [Related]
34. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
35. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast.
Munn KE; Walker RA; Varley JM
Oncogene; 1995 Apr; 10(8):1653-7. PubMed ID: 7731721
[TBL] [Abstract][Full Text] [Related]
36. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi OP; Isola J
Am J Pathol; 1997 Apr; 150(4):1465-71. PubMed ID: 9095001
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast.
Marsh KL; Varley JM
Br J Cancer; 1998 May; 77(9):1439-47. PubMed ID: 9652759
[TBL] [Abstract][Full Text] [Related]
38. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.
Tsuda H; Hirohashi S
Pathol Int; 1998 Jul; 48(7):518-25. PubMed ID: 9701014
[TBL] [Abstract][Full Text] [Related]
39. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia.
Tavassoli FA
Mod Pathol; 1998 Feb; 11(2):140-54. PubMed ID: 9504685
[TBL] [Abstract][Full Text] [Related]
40. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
